Welcome to our dedicated page for Lilly Eli & Co SEC filings (Ticker: LLY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Eli Lilly and Company (NYSE: LLY) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. These documents help investors understand Lilly’s capital structure, governance, financing activities and material events affecting the business.
Lilly’s common stock and several series of notes are registered under Section 12(b) of the Securities Exchange Act of 1934 and listed on the New York Stock Exchange, including common stock under the symbol LLY and multiple note series with maturities ranging from 2026 to 2061. Recent Form 8-K filings disclose items such as quarterly financial results furnished under Item 2.02, other events under Item 8.01, and governance changes under Item 5.02. For example, an August 2025 Form 8-K describes an underwriting agreement for floating-rate notes due 2028 and fixed-rate notes due between 2028 and 2065, while a November 2025 Form 8-K reports the election of a new independent director to Lilly’s board.
Through this page, users can review current and historical 8-Ks, along with other core filings such as annual reports on Form 10-K and quarterly reports on Form 10-Q when available. These filings typically include details on Lilly’s therapeutic focus areas—such as cardiometabolic health, obesity, oncology, immunology and neuroscience—its risk factors, research and development programs, and financial condition.
Stock Titan enhances access to Lilly’s filings by pairing real-time EDGAR updates with AI-powered summaries. AI-generated overviews can help explain the significance of complex documents, such as new debt offerings, governance changes or major transactions, in plain language. Users can also quickly identify insider and executive-related disclosures when they appear in Forms 3, 4 or 5, and track how financing decisions, such as multi-series note issuances, fit into Lilly’s broader capital strategy.
Whether you are analyzing LLY’s latest 10-K, reviewing 10-Q trends, or examining 8-Ks related to acquisitions, collaborations and manufacturing investments, this filings hub offers a structured view of the company’s regulatory record with tools to make dense disclosures easier to interpret.
Lilly Endowment Inc. has filed a Form 144 indicating a planned sale of 310,000 shares of Eli Lilly and Company common stock through J.P. Morgan Securities LLC, with an aggregate market value of 319,315,500. The filing notes that Eli Lilly had 945,383,757 shares outstanding at the time of the notice and lists 11/19/2025 as the approximate sale date on the NYSE or NASDAQ.
The securities to be sold trace back to common stock originally acquired by gift on 02/10/1948 from the J.K. Lilly Sr. Trust, in a transaction involving 38,400,000 shares. The notice also details a series of recent block sales of Eli Lilly common stock by Lilly Endowment Inc., including 351,015 shares sold on 10/01/2025 for 284,653,451.48 and 305,000 shares sold on 11/12/2025 for 308,411,211.50.
By signing, the seller represents that it is not aware of undisclosed material adverse information about Eli Lilly’s current or prospective operations.
Eli Lilly and Company director Kimberly H. Johnson reported buying 215.327 shares of Eli Lilly common stock on 11/17/2025. The Form 4 shows the shares were acquired at a price of $1,021.7 per share. After this transaction, she beneficially owns a total of 3,264.731 shares of Eli Lilly common stock directly.
Eli Lilly and Company director Gabrielle Sulzberger reported acquiring additional Eli Lilly (LLY) equity on Form 4. On 11/17/2025, she acquired 4.853 shares of common stock that, at her election, were deferred as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock after she leaves the board. On the same date, she also acquired 215.327 shares of common stock. Following these transactions, she reported beneficial ownership of 2,948.32 shares of common stock in direct ownership form.
Eli Lilly and Company director reports stock purchase. A reporting person serving as a director of Eli Lilly & Co (LLY) acquired 233.271 shares of common stock on 11/17/2025 at a price of $1,021.7 per share, according to a Form 4 filing. Following this transaction, the director beneficially owns 304.271 shares of Eli Lilly common stock in direct ownership.
Eli Lilly and Company director Juan R. Luciano reported acquiring a total of 229.845 shares of Lilly common stock on 11/17/2025. One transaction covered 14.518 shares that he elected to receive as stock units under the Lilly Directors' Deferral Plan instead of cash compensation, to be settled in shares after his separation from service. A second acquisition of 215.327 shares was also reported at a price of $1,021.7 per share. Following these transactions, Luciano directly beneficially owns 16,704.141 shares of Eli Lilly common stock.
Eli Lilly & Co director William G. Kaelin, Jr. reported an acquisition of company stock on a Form 4. On 11/17/2025, he acquired 215.327 shares of Eli Lilly common stock at a price of $1,021.7 per share. After this transaction, he beneficially owned a total of 21,836.814 Eli Lilly shares, held in direct ownership.
Eli Lilly & Co (LLY) director Jamere Jackson reported acquiring common stock of the company. On 11/17/2025, the reporting person acquired 215.327 shares of Eli Lilly common stock at a price of $1,021.7 per share, coded as an acquisition transaction. Following this transaction, the director beneficially owns 9,635.494 shares of Eli Lilly common stock held directly. The filing was made as a Form 4 by a single reporting person in the capacity of a company director.
Eli Lilly and Company director Mary Lynne Hedley reported acquiring additional common stock of LLY. On 11/17/2025, she acquired 9.706 shares of common stock and a separate 215.327-share award, both shown as acquisitions. The filing shows she beneficially owns 2,240.861 shares directly after these transactions, plus 98 shares held indirectly by a trust. According to the disclosure, the shares in one row were deferred in lieu of cash compensation into stock units under the Lilly Directors' Deferral Plan and will be settled in common stock after she separates from service.
Eli Lilly & Co. director reports additional stock units from fee deferral
A director of Eli Lilly & Co. (LLY) reported acquiring small amounts of common stock on 11/17/2025, shown as 9.706 and 215.327 shares, through transactions coded as acquisitions. According to the explanation, these amounts represent fees that the director elected to defer in the form of stock units under the Lilly Directors' Deferral Plan instead of taking cash compensation. The filing states these deferred stock units will be settled in shares of common stock after the director separates from service. Following these transactions, the director’s beneficial ownership is listed as 74,988.689 shares held directly.
Eli Lilly & Co (LLY) director Katherine Baicker reported a new stock purchase. On 11/17/2025, she acquired 215.327 shares of Eli Lilly common stock at a price of $1,021.7 per share. Following this transaction, she directly beneficially owns 23,502.628 shares of Eli Lilly common stock.